Compugen Ltd (CGEN) — SEC Filings
Compugen Ltd (CGEN) — 23 SEC filings. Latest: 6-K (Dec 17, 2025). Includes 21 6-K, 2 20-F.
View Compugen Ltd on SEC EDGAR
Overview
Compugen Ltd (CGEN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Dec 17, 2025: On December 16, 2025, Compugen Ltd. amended its license agreement with MedImmune Limited, a member of the AstraZeneca Group. Compugen sold a portion of its existing royalty interest in rilvegostomig to AstraZeneca for an upfront payment of $65 million.
Sentiment Summary
Across 23 filings, the sentiment breakdown is: 2 bullish, 21 neutral. The dominant filing sentiment for Compugen Ltd is neutral.
Filing Type Overview
Compugen Ltd (CGEN) has filed 21 6-K, 2 20-F with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (23)
Risk Profile
Risk Assessment: Of CGEN's 22 recent filings, 0 were flagged as high-risk, 1 as medium-risk, and 21 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Key Executives
- Eran Ophir, Ph.D.
- David Silberman
- Alberto Sessa
- Michelle Mahler, M.D.
- Anat C
Top Tags
sec-filing (10) · press-release (8) · financial-results (4) · foreign-private-issuer (4) · earnings (3) · form-6k (3) · corporate-governance (3) · shareholder-meeting (3) · filing (3) · biotechnology (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Upfront Payment | $65 million | Received by Compugen from AstraZeneca for royalty interest. |
| Quarterly Results | Q2 2025 | Financial performance for the second quarter of 2025. |
| Fiscal Year End | 1231 | Indicates the end of the reporting period for financial statements. |
| SEC File Number | 000-30902 | Unique identifier for Compugen's filings with the SEC. |
| Filing Date | 2024-03-05 | Date of submission |
| Reporting Period Start | 2023-01-01 | Fiscal year start |
Frequently Asked Questions
What are the latest SEC filings for Compugen Ltd (CGEN)?
Compugen Ltd has 23 recent SEC filings from Jan 2024 to Dec 2025, including 21 6-K, 2 20-F. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of CGEN filings?
Across 23 filings, the sentiment breakdown is: 2 bullish, 21 neutral. The dominant sentiment is neutral.
Where can I find Compugen Ltd SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Compugen Ltd (CGEN) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Compugen Ltd?
Financial highlights for Compugen Ltd are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for CGEN?
The investment thesis for CGEN includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Compugen Ltd?
Key executives identified across Compugen Ltd's filings include Eran Ophir, Ph.D., David Silberman, Alberto Sessa, Michelle Mahler, M.D., Anat C.
What are the main risk factors for Compugen Ltd stock?
Of CGEN's 22 assessed filings, 0 were flagged high-risk, 1 medium-risk, and 21 low-risk.
What are recent predictions and forward guidance from Compugen Ltd?
Forward guidance and predictions for Compugen Ltd are extracted from SEC filings as they are enriched.